A new report from the Grattan Institute has sparked a national conversation about the cost of community pharmacy services in Australia. The analysis suggests that the current funding model, which involves direct negotiations between the federal government and the Pharmacy Guild of Australia, results in excessive costs for taxpayers and patients. According to the report, some dispensing fees are not justified by the actual costs of providing services, and existing regulations may be stifling competition that could otherwise lower medicine prices for the public.
The Australian government spends nearly $4 billion annually on community pharmacy services. Under the current system, the Pharmacy Guild, which represents pharmacy owners, negotiates funding and policy directly with the government. The Grattan Institute argues that these negotiations often lack transparency and public evidence, leading to outcomes that prioritize the financial interests of pharmacy owners over the affordability of medicines for everyday Australians.
Key concerns raised in the report include rules that restrict where pharmacies can be located and who can own them. These regulations, combined with policies that discourage discounting on prescription medicines, are described as barriers to a more competitive market. The report suggests that if these protections were removed, patients could benefit from increased choice, longer opening hours, and lower out-of-pocket costs for their prescriptions.
To address these issues, the report recommends a significant shift in how pharmacy policy is managed. It proposes replacing the current closed-door bargaining process with independent, evidence-based decision-making. Additionally, it calls for a reset of dispensing fees to ensure they are based on actual costs rather than negotiated agreements. The report also suggests that the government should fund pharmacists to work within GP clinics, where their expertise could be better utilized to improve patient care.
As the debate continues, the focus remains on how to balance the need for a sustainable and accessible pharmacy network with the goal of keeping healthcare affordable. While the government has recently taken steps to reduce the cost of Pharmaceutical Benefits Scheme prescriptions, the Grattan Institute’s findings suggest that deeper structural reforms may be necessary to ensure the system delivers better value for both patients and taxpayers.